PT  - JOURNAL ARTICLE
AU  - TOMOYA TAGO
AU  - KENJI KATSUMATA
AU  - RYUTARO UDOU
AU  - KENTA KASAHARA
AU  - JUNICHI MAZAKI
AU  - HIROSHI KUWABARA
AU  - MASANOBU ENOMOTO
AU  - TETSUO ISHIZAKI
AU  - YUICHI NAGAKAWA
AU  - KATSUTOSHI SUGIMOTO
AU  - TAKAO ITOI
AU  - AKIHIKO TSUCHIDA
TI  - Significance of Radiofrequency Ablation for Unresectable Colorectal Cancer With Liver Metastases
AID  - 10.21873/anticanres.15367
DP  - 2021 Nov 01
TA  - Anticancer Research
PG  - 5539--5547
VI  - 41
IP  - 11
4099  - http://ar.iiarjournals.org/content/41/11/5539.short
4100  - http://ar.iiarjournals.org/content/41/11/5539.full
SO  - Anticancer Res2021 Nov 01; 41
AB  - Background/Aim: We aimed to investigate the prognosis of patients who received radiofrequency ablation (RFA) for liver metastases of unresectable colorectal cancer (CRC). Patients and Methods: We retrospectively compared 147 patients treated for CRC liver metastases, who underwent RFA (n=26), resection (n=92), and chemotherapy (n=29) between 2001 and 2021. Results: RFA and chemotherapy were performed for unresectable or non-operable cases, and resection was performed for suitable cases. The median overall survival (OS) was 44.9, 49.5, and 11.6 months for patients who underwent RFA, resection, and chemotherapy, respectively. RFA led to a significantly shorter OS compared to resection (p=0.027) but to a longer OS compared to chemotherapy (p=0.003). The 5-year survival rates were 34.6% and 42.4% for patients who underwent RFA and resection, respectively (p=0.508). Conclusion: RFA has the potential to achieve long-term survival or radical cure, even for unresectable or non-operable cases of CRC with liver metastasis.